Weight gain and metabolic syndrome among young patients on antipsychotic medication: what do we know and where do we go?
Weight gain and metabolic syndrome among young patients on antipsychotic medication: what do we know and where do we go?
复制标题
DOI：
10.3109/10398562.2010.539609
复制
发表时间：
2011-06-01
影响因子：
1.8
通讯作者：
John, George
中科院分区：
文献类型：
--
作者：
Eapen, Valsamma;John, George
目的：儿童肥胖及其后遗症，包括代谢综合征，在世界范围内正达到流行的程度。接受抗精神病药物治疗的年轻人尤其面临风险，因为他们经历了第二代抗精神病药物（SGAs）的副作用，体重显著增加，从而增加了2型糖尿病，心血管发病率和代谢综合征的风险。然而，在常规临床实践中，既没有对这些副作用进行监测，也没有提供干预。本文探讨了目前的证据在这个问题上的状态，并提出了未来的研究和临床practice.Conclusions方向：系统的监测和预防计划，旨在体重增加和代谢的副作用，应形成一个不可分割的一部分，青少年对SGAs的综合管理。
Objective: Childhood obesity and its sequelae, including metabolic syndrome, are reaching epidemic proportions worldwide. Young people treated with antipsychotic medication are particularly at risk as they experience significant weight gain as a side effect of second generation antipsychotics (SGAs) with consequent increased risk of type 2 diabetes, cardiovascular morbidity and metabolic syndrome. However, surveillance for these side effects is not carried out nor intervention offered in routine clinical prctice. This paper examines the current state of evidence on this topic and suggests directions for future research and clinical practice.Conclusions: Systematic monitoring and preventative programs aimed at weight gain and metabolic side effects should form an integral part of the comprehensive management of adolescents on SGAs.